NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
09/23/2025
Back to search
Official data from USPTO
TIGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000079311144Class
1, 5, 10, 42, 44
Filing
79311144
Registration
7691049
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
56
Latest update
09/23/2025
Trademark type
Combined
Nice classes
1, 5, 10, 42, 44
Filing date
02/04/2021
Registration date
02/18/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/18/2025
Last transaction
09/23/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
33
Owner location
CH
Examiner
AGREDA, SAMANTHA
Current location
Historical data usage
Holders and representatives
Holders
Tigen Pharma SA
Representatives
STACEY HALPERN KNOBBE MARTENS OLSON & BEAR LLP
Technical classification
Nice Classes
Class 1Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiochemicalbiological and biotechnological preparationspolypeptides and proteinsfor use in industry and science; chemicalbiochemicalbiological and biotechnological preparationspolypeptides and proteinsfor use in the development being the manufacturemanufacture of reagents for industrial or scientific use; chemicalbiochemicalbiological and biotechnological preparationspolypeptides or proteinsfor use of laboratoriesdiagnostics and analyses for industrial or scientific use; chemicalbiochemicalbiological and biotechnological substancespolypeptides and proteinsfor use in the manufacture of pharmaceuticals * ; all the above-mentioned goods exclusively for use in the fields of anti-cancer therapies and other cell and/or genetic therapiesexcept emulsifiers *
Class 5
Pharmaceutical products and medical preparationsgene-modified and non-gene-modified cellular therapies for the treatment of localized and systemic malignant hematological and oncological diseasesgenetic diseasesautoimmune diseases and infectious diseases
Class 10
Medical instrumentsequipment and apparatusinstrumentsequipment and apparatus for cell and cell material collectionthawingwashingselectionexpansionmodificationharvestingfinal formulationfreezingstorage and infusion into a patient in the fields of genetic diseasesautoimmune diseasesinfectious diseaseslocalized and systemic malignant hematological and oncological diseases and other cell and cell-material based diseases and conditions
Class 42
Scientific researchtechnological development of new products for third parties; medical research; scientific and industrial research in biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious and tumor diseases; research in the field of biomedical and phytopharmaceutical technology; scientific laboratory services; pharmaceutical research and development services; scientific servicesdevelopment of medicinesactive substances and vaccines; scientific servicesdevelopment of food supplement; design and development of computer hardware and software for use in medical and scientific research and in the development of new productsin research and development of new products in the field of biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases; upgradingmaintenance and rental of computer software; updatingmaintenance and rental of computer software for use in medical and scientific research and in the development of new productsin research and development of new products in the field of biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases; software as a service (SaaS) services featuring software for controlling end-to-end process developmentmanufacturingqualitysupply chain steps and featuring artificial intelligence search engine software to be used in medical and scientific research and in the development of new products in research and development of new products in the field of biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases; chemical and biological laboratory services
Class 44
Medical services; pharmacy advice servicespharmaceutical consultation; medical clinic services provided by medical laboratories for diagnostic purposes; preparation and dispensing of medication; preparation of prescriptions by pharmacists
Publications
History of USPTO decisions and trademark events.
56 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/19/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/02/2025
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
09/02/2025
FIMP
FINAL DISPOSITION PROCESSED
09/02/2025
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
09/02/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/02/2025
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
08/29/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
06/13/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
06/06/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/18/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/18/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
02/18/2025
TMBN
TTAB RELEASE CASE TO TRADEMARKS
01/29/2025
OP.T
OPPOSITION TERMINATED NO. 999999
01/29/2025
OP.D
OPPOSITION DISMISSED NO. 999999
01/29/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/31/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/11/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/08/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/08/2023
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
08/02/2022
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
06/05/2022
RFNT
REFUSAL PROCESSED BY IB
04/10/2022
OP.I
OPPOSITION INSTITUTED NO. 999999
03/28/2022
OPNS
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
03/16/2022
OPNC
OPPOSITION NOTICE (IB REFUSAL) CREATED
03/16/2022
OPPF
OPPOSITION PAPERS RECEIVED AT TTAB
03/15/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/15/2022
PUBO
PUBLISHED FOR OPPOSITION
02/15/2022
GPNX
NOTIFICATION PROCESSED BY IB
02/14/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/26/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/26/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/26/2022
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/11/2022
ALIE
ASSIGNED TO LIE
01/11/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/10/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
01/10/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/10/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
01/10/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/10/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/07/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/07/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/07/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/07/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/07/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/07/2022
RFNT
REFUSAL PROCESSED BY IB
10/04/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/14/2021
RFRR
REFUSAL PROCESSED BY MPU
09/14/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/14/2021
CNRT
NON-FINAL ACTION WRITTEN
09/13/2021
DOCK
ASSIGNED TO EXAMINER
08/27/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/20/2021
MAFR
APPLICATION FILING RECEIPT MAILED
05/25/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/21/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/20/2021
Continuous trademark protection
Get notified about every new filing that threatens TIGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.